MarketCap
Facebook
X
TelegramQuarterly report 2026-Q1
added 05-15-2026
Predictive Oncology Interest Expense 2011-2026 | POAI
Interest expense is the amount of interest a company is obligated to pay to creditors for using debt financing (bank loans, bonds, leasing, etc.) during the reporting period.Includes:
- Interest on bank loans
- Interest on corporate bonds
- Interest on leases
- Interest on credit lines and overdrafts
High interest expenses indicate a high debt burden — the company may be vulnerable to rising rates or declining revenue.
Low interest expenses with high profits are a sign of financial stability.
Annual Interest Expense Predictive Oncology
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2005 | 2004 | 2003 | 2002 | 2001 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| - | - | - | - | - | - | - | - | - | 3 | 391 K | 378 K | 637 K | 259 K | 230 K | 147 K | - | - | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 637 K | 3 | 292 K |
Quarterly Interest Expense Predictive Oncology
| 2026-Q1 | 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | -3.22 K | - | - | - | - | - | - | - | - | - | - | 3 | - | - | - | 51.8 K | 189 K | 154 K | - | 132 K | 14.8 K | 18.1 K | - | 408 K | 127 K | 95.6 K | - | 23.7 K | 89.3 K | 55.5 K | - | 61 K | 57.9 K | 57.9 K |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 408 K | -3.22 K | 90.1 K |
Interest Expense of other stocks in the Medical instruments industry
| Issuer | Interest Expense | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
Atrion Corporation
ATRI
|
149 | - | - | $ 810 M |  USA |
 |
The Cooper Companies
COO
|
-16.4 M | $ 62.02 | 2.78 % | $ 12.3 B | USA |
 |
Glaukos Corporation
GKOS
|
479 K | $ 121.69 | 7.08 % | $ 6.96 B | USA |
 |
Alcon
ALC
|
204 M | $ 66.58 | 3.67 % | $ 40.4 B |  Schweiz |
 |
ICU Medical
ICUI
|
93.3 M | $ 134.93 | 3.38 % | $ 3.32 B | USA |
 |
iRhythm Technologies
IRTC
|
5.44 M | $ 107.35 | 2.67 % | $ 3.44 B | USA |
 |
Repro Med Systems
KRMD
|
9.91 K | $ 4.14 | 5.61 % | $ 191 M | USA |
 |
LeMaitre Vascular
LMAT
|
5.18 M | $ 93.56 | 2.1 % | $ 2.12 B | USA |
 |
Masimo Corporation
MASI
|
300 K | $ 178.9 | 0.07 % | $ 9.54 B | USA |
 |
Microbot Medical
MBOT
|
-5 K | $ 1.96 | -0.51 % | $ 89.7 M |  Israel |
 |
Ekso Bionics Holdings
EKSO
|
-26 K | - | - | $ 28.6 M | USA |
 |
Milestone Scientific
MLSS
|
60.3 K | $ 0.43 | 11.28 % | $ 35.3 M | USA |
 |
electroCore
ECOR
|
14.9 K | $ 9.94 | 0.81 % | $ 84.3 K | USA |
 |
Envista Holdings Corporation
NVST
|
-2.3 M | $ 22.87 | 2.1 % | $ 3.84 B | USA |
 |
Haemonetics Corporation
HAE
|
-28.7 M | $ 69.85 | 6.03 % | $ 3.3 B | USA |
 |
Isoray
ISR
|
84 K | - | 0.03 % | $ 108 M | USA |
 |
STERIS plc
STE
|
9.8 M | $ 212.24 | 0.98 % | $ 20.8 B | USA |
 |
STAAR Surgical Company
STAA
|
2.25 M | $ 29.86 | 5.66 % | $ 1.48 B | USA |
 |
InfuSystem Holdings
INFU
|
2 K | $ 9.12 | 1.0 % | $ 188 M | USA |
 |
Teleflex Incorporated
TFX
|
85.1 M | $ 132.11 | 2.76 % | $ 5.9 B | USA |
 |
Merit Medical Systems
MMSI
|
-2.39 M | $ 63.04 | 3.94 % | $ 3.73 B | USA |
 |
Utah Medical Products
UTMD
|
-120 K | $ 67.99 | 3.75 % | $ 220 M | USA |
 |
West Pharmaceutical Services
WST
|
-1 M | $ 317.32 | 0.32 % | $ 22.9 B | USA |
 |
DENTSPLY SIRONA
XRAY
|
24 M | $ 9.88 | 2.49 % | $ 1.97 B | USA |
 |
Pulse Biosciences
PLSE
|
-52 K | $ 26.94 | 7.8 % | $ 1.82 B | USA |
 |
Retractable Technologies
RVP
|
152 K | $ 0.66 | 0.41 % | $ 19.8 M | USA |
 |
Pro-Dex
PDEX
|
533 K | $ 67.0 | 2.81 % | $ 220 M | USA |
 |
BioLife Solutions
BLFS
|
1.82 M | $ 27.09 | -0.59 % | $ 1.29 B | USA |
 |
Stereotaxis
STXS
|
2 K | $ 1.88 | 2.17 % | $ 171 M | USA |
 |
Baxter International
BAX
|
290 M | $ 19.35 | 4.37 % | $ 9.93 B | USA |
 |
ResMed
RMD
|
3.2 M | $ 194.32 | 4.22 % | $ 28.4 B | USA |
 |
AtriCure
ATRC
|
683 K | $ 27.27 | 4.08 % | $ 1.3 B | USA |
 |
Harvard Bioscience
HBIO
|
-2.66 M | $ 6.48 | -0.31 % | $ 288 M | USA |
 |
AngioDynamics
ANGO
|
4.94 M | $ 12.03 | 7.41 % | $ 491 M | USA |
 |
Becton, Dickinson and Company
BDX
|
613 M | $ 149.56 | 2.73 % | $ 43 B | USA |
 |
Nephros
NEPH
|
-78 K | $ 3.59 | -1.37 % | $ 38.1 M | USA |
 |
OraSure Technologies
OSUR
|
229 K | $ 4.17 | 5.57 % | $ 306 M | USA |
 |
Repligen Corporation
RGEN
|
2.82 M | $ 126.55 | 3.96 % | $ 7.12 M | USA |